Evolution of Glucocorticosteroid Prescribing in DMD Over the Decade

Glucocorticosteroids remain the cornerstone of pharmacological management in Duchenne muscular dystrophy (DMD). Over the past decade, clinical research has continuously reshaped how clinicians approach long-term corticosteroid administration. Real-world evidence demonstrates that glucocorticosteroid prescribing in DMD has undergone notable transitions regarding drug selection, dosing frequency, and adverse effect surveillance. The UK NorthStar Clinical Network recently published comprehensive longitudinal registry data evaluating over a decade of clinical practice across 1,117 boys. These findings offer invaluable real-world perspective on contemporary treatment strategies.

Historically, clinicians initiated glucocorticoids primarily to prolong independent ambulation, preserve pulmonary mechanics, and delay progressive scoliosis. However, real-world registry analysis indicates that clinical protocols have evolved significantly beyond initial standardized recommendations. For instance, while prednisolone was once the ubiquitous first-line agent, modern pediatric neurologists increasingly tailor therapy to mitigate specific adverse reactions. Moreover, ongoing clinical trials comparing daily versus intermittent schedules have heavily influenced specialist prescribing habits. Consequently, treatment choices today reflect a nuanced balance between functional motor gains and metabolic safety.

The Shift Toward Deflazacort and Daily Treatment Regimens

During the eleven-year observation period from 2012 to 2022, significant shifts occurred in the choice of corticosteroid molecules. Although prednisolone accounted for 65% of all clinical assessments across the study timeframe, deflazacort prescribing increased markedly. Specifically, deflazacort prescriptions rose from 17% of patients in 2012 to 43% in 2022. This clear upward trajectory illustrates an expanding preference among specialists for deflazacort, particularly when managing long-term weight gain, body composition, and behavioral changes.

Simultaneously, treatment schedules demonstrated a pronounced shift toward continuous daily administration. Daily regimens accounted for approximately 66% of assessments throughout the decade. In contrast, the classic intermittent regimen consisting of ten days on medication followed by ten days off saw substantial decline. While 46% of boys followed an intermittent schedule in 2012, this proportion fell to just 26% by 2022. Furthermore, comparative efficacy data from multicenter clinical trials have continually reinforced the motor benefits of daily dosing. Therefore, many pediatric centers switched ambulatory boys from intermittent to daily protocols to maximize muscle preservation during critical developmental windows.

Dosage Trends and Underdosing Patterns in Older Children

Optimal therapeutic dosing represents a continuous clinical challenge as boys with DMD grow older. Standard international care guidelines recommend target doses of 0.75 mg/kg/day for prednisolone and 0.9 mg/kg/day for deflazacort. However, longitudinal registry findings revealed that older boys were frequently maintained on doses substantially below these published recommendations. This trend of sub-target dosing became increasingly evident as patients advanced into their late childhood and teenage years.

Notably, underdosing occurred more frequently among boys prescribed deflazacort or those following daily regimens. As boys gain weight or experience cumulative steroid side effects, clinicians frequently cap total daily doses rather than continuing strict weight-based increments. Consequently, absolute milligram caps prevent excessive toxicity, but they effectively lower relative milligram-per-kilogram exposure. Furthermore, managing the adolescent transition requires clinicians to balance progressive muscle loss against severe glucocorticoid toxicity. Hence, routine dosing adjustments in older boys reflect pragmatic clinical decisions to sustain tolerability.

Adverse Effect Profiles: Prednisolone Versus Deflazacort

Long-term corticosteroid therapy inevitably involves managing predictable multi-organ adverse effects. The NorthStar registry data delineated important differences in side-effect profiles between specific corticosteroid agents and administration schedules. Interestingly, gastrointestinal symptoms and cushingoid features were documented more frequently in boys treated with deflazacort than in those receiving prednisolone. This finding challenges historical assumptions that deflazacort universally confers superior cosmetic and gastrointestinal tolerability.

Additionally, administration schedules heavily modulated the nature and frequency of reported side effects. Patients on daily regimens experienced significantly higher rates of increased appetite, cushingoid appearance, gastrointestinal complaints, and insomnia compared to those on intermittent regimens. In contrast, intermittent dosing schedules reduced systemic steroid exposure, thereby mitigating several metabolic and behavioral toxicities. Nevertheless, clinicians often accepted higher side-effect risks with daily therapy because of superior functional preservation. Therefore, proactive monitoring for hypertension, cataracts, growth deceleration, and vertebral fractures remains mandatory regardless of the chosen molecule.

Clinical Implications for Pediatric Neuromuscular Practice

The evolving real-world patterns of glucocorticoid use offer essential practical lessons for pediatricians, neurologists, and multidisciplinary neuromuscular teams. First, the progressive transition toward deflazacort and daily schedules underscores the clinical necessity of early baseline assessments and proactive toxicity monitoring. Clinicians must establish structured surveillance protocols for bone health, linear growth velocity, metabolic parameters, and behavioral health right from treatment initiation.

Furthermore, therapy should not follow a rigid, one-size-fits-all model across a patient's lifespan. When excessive weight gain, behavioral disturbances, or gastrointestinal intolerance arise, switching between prednisolone and deflazacort remains a valid strategy. Similarly, adjusting dosing schedules or implementing dose caps in older non-ambulatory adolescents helps maintain vital upper limb and respiratory function while preserving quality of life. Ultimately, longitudinal real-world evidence reminds clinicians that individualized care, shared family decision-making, and proactive multidisciplinary management are essential to maximize long-term therapeutic outcomes.

Guideline Alignment and Long-Term Patient Monitoring

Translating observational registry evidence into daily clinical workflows requires strict alignment with established international consensus guidelines. Pediatric neuromuscular guidelines emphasize that glucocorticoid initiation should ideally occur before significant functional decline begins, typically around four to five years of age. Routine monitoring every six months must evaluate motor function, vital capacity, bone mineral density, and spinal alignment to detect deterioration early.

Moreover, clinicians must actively prepare families for potential adverse effects by recommending dietary modifications, calcium and vitamin D supplementation, and scheduled ophthalmological examinations. Because sudden discontinuation poses serious risks of life-threatening adrenal crisis, caregivers must receive explicit education regarding stress-dose steroid coverage during acute intercurrent illnesses or surgeries. By combining rigorous surveillance with flexible regimen optimization, physicians can successfully prolong ambulation and safeguard patient well-being.

Frequently Asked Questions

What is the primary difference in clinical usage between prednisolone and deflazacort in DMD?

Prednisolone and deflazacort both prolong ambulation and preserve upper-body strength in boys with Duchenne muscular dystrophy. Deflazacort causes less excessive weight gain in many patients, whereas prednisolone remains widely accessible and cost-effective. However, deflazacort is associated with higher rates of growth delay, cataracts, and cushingoid features.

Why are daily glucocorticosteroid regimens preferred over intermittent dosing schedules?

Daily glucocorticosteroid regimens provide superior motor functional preservation, prolonging independent walking and stabilizing respiratory capacity longer than intermittent schedules. Although intermittent protocols lower cumulative drug toxicity, clinical trials show daily dosing maintains muscle membrane stability more effectively. Therefore, guidelines strongly advocate daily administration as the primary initial therapeutic strategy.

How should clinicians manage glucocorticosteroid dosing in older or non-ambulatory DMD patients?

Clinicians managing older or non-ambulatory boys often implement absolute dose caps to prevent severe metabolic and bone toxicities. Rather than continually increasing doses by body weight, specialists adjust doses to maintain upper-extremity strength and respiratory function. Furthermore, regular monitoring for osteoporosis, hypertension, and adrenal suppression remains critically important.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice or to be used for establishing a diagnosis or treatment. The clinical evaluations, comments, opinions and other insights provided are the personal viewpoints of the authors and do not represent any official stance or endorsement by any institution. Readers should consult qualified healthcare professionals before making any health-related decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Landon G et al. Observational study of changes to glucocorticosteroid prescribing patterns in duchenne muscular dystrophy in the UK over the last decade. J Neurol Neurosurg Psychiatry. 2025 Jul 16. doi: 10.1136/jnnp-2024-335223. PMID: 39939137.


2. Guglieri M et al. Efficacy and Safety of Daily Prednisone, Daily Deflazacort, and Intermittent Prednisone in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial (FOR-DMD). JAMA. 2022;327(15):1456–1468.


3. Birnkrant DJ et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267.


4. McDonald CM et al. Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent trials. Muscle Nerve. 2020;61(1):26-35.